CureVac N.V (CVAC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CVAC Stock Price Chart Interactive Chart >
CVAC Price/Volume Stats
| Current price | $9.15 | 52-week high | $20.49 |
| Prev. close | $9.38 | 52-week low | $5.63 |
| Day low | $9.10 | Volume | 6,509,911 |
| Day high | $9.45 | Avg. volume | 1,955,681 |
| 50-day MA | $8.65 | Dividend yield | N/A |
| 200-day MA | $11.18 | Market Cap | 1.71B |
CureVac N.V (CVAC) Company Bio
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)
Latest CVAC News From Around the Web
Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.
CureVac Announces Proposed Public Offering of Common SharesCureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering. |
CureVac Welcomes Myriam Mendila as New Chief Development Officer/ CureVac N.V. |
Why did CureVac stock slip today? Declining market for COVID vaccines (NASDAQ:CVAC)CureVac (CVAC) shares dropped ~7% Tuesday likely due to comments Pfizer made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine. |
EQS-News: CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexisIssuer: CureVac / Key word(s): Patent CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis 31.01.2023 / 14:12 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis |
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)/ CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its inclusion in the second annual "Innovation Momentum: Global Top 100" report by LexisNexis®. Top 100 recognizes companies advancing innovative solutions to address today's challenges and laying the intellectual property foundations for further breakthroughs. |
CVAC Price Returns
| 1-mo | -11.68% |
| 3-mo | 24.32% |
| 6-mo | -32.12% |
| 1-year | -49.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 51.74% |
| 2022 | -82.42% |
| 2021 | -57.68% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...